Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length

L E Heisler1, A Evangelou, A M Lew

  • 1Division of Reproductive Science, Toronto Hospital Research Institute, Ontario, Canada.

Insights

Androgen receptor (AR) expression in prostate cancer cells paradoxically inhibits growth and induces apoptosis, even at low levels. This suggests a complex role for AR in advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Androgen receptor (AR) is crucial in prostate cancer development.
  • Androgen-independent prostate cancer (PCa) often lacks AR expression.
  • Understanding AR function in advanced PCa is critical for treatment strategies.

Purpose of the Study:

  • To investigate the functional role of the androgen receptor (AR) in androgen-independent prostate cancer cells.
  • To determine the effects of AR re-expression and androgen stimulation on PC-3 cell growth and survival.

Main Methods:

  • Transfection of PC-3 cells (lacking AR) with human AR cDNA.
  • Assessment of AR expression using immunoblotting and ligand binding assays.
  • Analysis of androgen-inducible gene expression using MMTV-luciferase reporter.
  • Cell growth, cell cycle, and apoptosis assays following DHT treatment.

Main Results:

  • Exogenous AR expression in PC-3 cells mediated androgen-inducible reporter gene activity.
  • Physiological levels of 5 alpha-dihydrotestosterone (DHT) paradoxically inhibited PC-3 cell growth.
  • DHT treatment led to cell cycle arrest in G1 phase and induced apoptosis.
  • DHT withdrawal could rescue cells from death if initiated early, but not after prolonged exposure.

Conclusions:

  • Re-expression of AR in androgen-independent PC-3 cells confers sensitivity to androgens.
  • DHT induces growth inhibition and apoptosis in AR-expressing PC-3 cells, independent of AR overexpression levels.
  • These findings suggest a complex, potentially tumor-suppressive role for AR in certain contexts of advanced prostate cancer.